Epizyme Inc (NASDAQ:EPZM) insider Matthew Ros sold 1,185 shares of the firm’s stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $12.10, for a total transaction of $14,338.50. Following the completion of the sale, the insider now owns 40,217 shares of the company’s stock, valued at approximately $486,625.70. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of NASDAQ EPZM traded down $0.37 during midday trading on Friday, reaching $11.63. The company’s stock had a trading volume of 669,357 shares, compared to its average volume of 878,828. The company has a quick ratio of 12.55, a current ratio of 12.55 and a debt-to-equity ratio of 0.03. Epizyme Inc has a fifty-two week low of $5.14 and a fifty-two week high of $16.10. The company has a market capitalization of $1.09 billion, a PE ratio of -6.76 and a beta of 2.73.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. The company had revenue of $7.89 million during the quarter, compared to analyst estimates of $1.13 million. As a group, sell-side analysts expect that Epizyme Inc will post -2 EPS for the current year.
Several research analysts have recently issued reports on the stock. Cowen reaffirmed a “buy” rating and issued a $18.00 target price on shares of Epizyme in a research note on Tuesday, February 26th. BidaskClub raised shares of Epizyme from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Oppenheimer reduced their target price on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 27th. Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a research note on Wednesday, February 27th. Finally, ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Wednesday, February 27th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Epizyme has a consensus rating of “Buy” and a consensus price target of $18.90.
A number of hedge funds and other institutional investors have recently modified their holdings of EPZM. Legal & General Group Plc raised its stake in Epizyme by 16.9% during the fourth quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 1,455 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Epizyme during the fourth quarter worth about $76,000. Exane Derivatives acquired a new position in Epizyme during the first quarter worth about $84,000. Metropolitan Life Insurance Co. NY raised its stake in Epizyme by 326.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,541 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 12,663 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Epizyme during the first quarter worth about $135,000. 84.14% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.thestockobserver.com/2019/06/15/matthew-ros-sells-1185-shares-of-epizyme-inc-nasdaqepzm-stock.html.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
See Also: What is the QQQ ETF?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.